	US 11,866,480 B2
	Vector-mediated immune tolerance in the eye
Matthew Louis Hirsch, Chapel Hill, NC (US); and Brian Christopher Gilger, Raleigh, NC (US)
Assigned to The University of North Carolina at Chapel Hill, Chapel Hill, NC (US); and North Carolina State University, Raleigh, NC (US)
Appl. No. 16/318,070
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US); and North Carolina State University, Raleigh, NC (US)
PCT Filed Jul. 26, 2017, PCT No. PCT/US2017/043831 § 371(c)(1), (2) Date Jan. 15, 2019, PCT Pub. No. WO2018/022683, PCT Pub. Date Feb. 1, 2018.
Claims priority of provisional application 62/366,822, filed on Jul. 26, 2016.
Prior Publication US 2021/0292388 A1, Sep. 23, 2021
Int. Cl. C07K 14/705 (2006.01); C07K 14/74 (2006.01); A61P 27/02 (2006.01); A61P 37/06 (2006.01); A61K 9/00 (2006.01); C12N 15/86 (2006.01)

CPC C07K 14/70539 (2013.01) [A61K 9/0048 (2013.01); A61P 27/02 (2018.01); A61P 37/06 (2018.01); C12N 15/86 (2013.01); C12N 2750/14142 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01); C12N 2830/50 (2013.01)]

18 Claims

1. A polynucleotide encoding human leukocyte antigen-G (HLA-G), wherein the nucleotide sequence has been codon-optimized for expression in human cells, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1, wherein the polynucleotide provides an approximately three-fold increase in expression of HLA-G in human cells relative to the wild-type nucleotide sequence encoding HLA-G tested under otherwise identical conditions.

17. A polynucleotide encoding human leukocyte antigen-G (HLA-G), wherein the nucleotide sequence has been codon-optimized for expression in human cells, wherein the polynucleotide comprises a nucleotide sequence at least 95% identical to SEQ ID NO: 2.